top of page

英文論文業績一覧

・Tetsu Hayashida, Hiromitsu Jinno, Katsuaki Mori, Hiroki Sato, Akira Matsui, Takashi Sakurai , Hiroaki Hattori, Shin Takayama, Masahiro Wada, Maiko Takahashi, Hirohito Seki, Tomoko Seki, Aiko Nagayama, Akiko Matsumot, Yuko Kitagawa, Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial., BMC Cancer. 2018 Jun 28;18(1):701.

・Matsumoto A, Hayashida T, Takahashi M, Jinno H, Kitagawa Y, Antitumor effect of lapatinib and cytotoxic agents by suppression of E2F1 in HER2‑positive breast cancer, Mol Med Rep. 2018

 

・Murata T, Jinno H, Takahashi M, Shimoda M, Hayashida T, Kameyama K, Kitagawa Y. Clinicopathologic features of hormone-receptor-positive breast cancer patients with late recurrence. Breast J. 2018 

 

・Ayako Nakashoji, Tetsu Hayashida, Takamichi Yokoe, Hinako Maeda, Tomoka Toyota, Masayuki Kikuchi, Rurina Watanuki, Aiko Nagayama, Tomoko Seki, Maiko Takahashi, Takayuki Abe, Yuko Kitagawa, The updated network meta-analysis of neoadjuvant therapy for HER2-positive breast cancer, Cancer Treat Rev. 2018 

 

・Shimada Y, Kameyama H, Nagahashi M, Ichikawa H, Muneoka Y, Yagi R, Tajima Y, Okamura T, Nakano M, Sakata J, Kobayashi T, Nogami H, Maruyama S, Takii Y, Hayashida T, Takaishi H, Kitagawa Y, Oki E, Konishi T, Ishida F, Kudo SE, Ring JE, Protopopov A, Lyle S, Ling Y, Okuda S, Ishikawa T, Akazawa K, Takabe K, Wakai T., Comprehensive genomic sequencing detects important genetic differences between right-sided and left-sided colorectal cancer., Oncotarget. 2017 

 

・Takesue T, Kawakubo H, Hayashida T, Tsutsui M, Miyao K, Fukuda K, Nakamura R, Takahashi T, Wada N, Takeuchi H, Kitagawa Y., Downregulation of cytochrome c oxidase 1 induced radioresistance in esophageal squamous cell carcinoma., Oncol Lett.

 

・Kitahata R, Nakajima S, Uchida H, Hayashida T, Takahashi M, Nio S, Hirano J, Nagaoka M, Suzuki T, Jinno H, Kitagawa Y, Mimura M., Masaru Mimura Self-rated Cognitive Functions Following Chemotherapy in Patients with Breast Cancer: A 6-month Prospective Study, Neuropsychiatr Dis Treat. 2017 

 

・Seki T, Hayashida T, Takahashi M, Jinno H, Kitagawa Y. A randomized controlled study comparing a vessel sealing system with the conventional technique in axillary lymph node dissection for primary breast cancer. Springerplus. 2016 

 

・Sho Shimamura, Motoko Kanegae, Jun Morita, Yuji Uema, Maiko Takahashi, Masahiko Inami, Tetsu Hayashida, Hideo Saito, Maki Sugimoto, Virtual Slicer: Visualizer for Tomographic Medical Images Corresponding Handheld Device to Patient, The International Journal of Virtual Reality, 2015, 15 (01): 10-17

・Matsumoto A, Jinno H, Ando T, Fujii T, Nakamura T, Saito J, Takahashi M, Hayashida T, Kitagawa Y., Biological markers of invasive breast cancer., Jpn J Clin Oncol. 2015 

 

・Matsumoto A, Jinno H, Nakamura T, Saito J, Takahashi M, Hayashida T, Kameyama K, Kitagawa Y. Technical feasibility of sentinel lymph node biopsy in patients with ipsilateral breast tumor recurrence and previous axillary surgery. Int J Surg. 2015 Aug 13. pii: S1743-9191(15)01096-1. doi: 10.1016/j.ijsu.2015.07.709.

 

・Tsutsui M, Kawakubo H, Hayashida T, Fukuda K, Nakamura R, Takahashi T, Wada N, Saikawa Y, Omori T, Takeuchi H, Kitagawa Y. Comprehensive screening of genes resistant to an anticancer drug in esophageal squamous cell carcinoma. Int J Oncol. 2015 Sep;47(3):867-74. doi: 10.3892/ijo.2015.3085.

 

・T Seki, H Jinno, K Okabayashi, T Murata, A Matsumoto, M Takahashi, T Hayashida, Y Kitagawa, Comparison of oncological safety between nipple sparing mastectomy and total mastectomy using propensity score matching, Annals of The Royal College of Surgeons of England 05/2015; 97(4). DOI:10.1308/003588415X14181254788881

 

・Nagayama A, Hayashida T, Jinno H, Takahashi M, Kitagawa Y. Response. J Natl Cancer Inst. 2015 Mar 3;107(4). pii: djv039. doi: 10.1093/jnci/djv039. Print 2015 Apr.

 

・Tanaka M, Shinoda M, Takayanagi A, Oshima G, Nishiyama R, Fukuda K, Yagi H, Hayashida T, Masugi Y, Suda K, Yamada S, Miyasho T, Hibi T, Abe Y, Kitago M, Obara H, Itano O, Takeuchi H, Sakamoto M, Tanabe M, Maruyama I, Kitagawa Y. Gene transfer of high-mobility group box 1 box-A domain in a rat acute liver failure model. J Surg Res. 2014 Nov 22. pii: S0022-4804(14)01058-0. doi: 10.1016/j.jss.2014.11.022.

 

・Matsumoto A, Jinno H, Murata T, Seki T, Takahashi M, Hayashida T, Kameyama K, Kitagawa Y. Prognostic implications of receptor discordance between primary and recurrent breast cancer., Int J Clin Oncol. 2015 Aug;20(4):701-8. doi: 10.1007/s10147-014-0759-2.

 

・Aiko Nagayama, Tetsu Hayashida, Hiromitsu Jinno, Maiko Takahashi, Tomoko Seki, Akiko Matsumoto, Takeshi Murata, Hutan Ashrafian, Thanos Athanasiou, Koji Okabayashi, and Yuko Kitagawa, Comparative effectiveness of neoadjuvant therapy for HER2-positive breast cancer: A network meta-analysis. J Natl Cancer Inst. (2014) 106 (9): dju203. doi: 10.1093/jnci/dju203

 

・Zhussupova A, Hayashida T, Takahashi M, Miyao K, Okazaki H, Jinno H, Kitagawa Y. An E2F1-HOXB9 Transcriptional Circuit Is Associated with Breast Cancer Progression. PLoS One. 2014 Aug 19;9(8):e105285. doi: 10.1371/ journal.pone. 0105285.

 

・Yoshinori Hoshino, Tetsu Hayashida, Akira Hirata, Hidena Takahashi, Naokazu Chiba, Mitsuyo Ohmura, Masatoshi Wakui, Hiromitsu Jinno, Hirotoshi Hasegawa, Shyamala Maheswaran, Makoto Suematsu, Yuko Kitagawa, Bevacizumab terminates homeobox B9-induced tumor proliferation by silencing microenvironmental communication. Mol Cancer. 2014 May 5;13(1):102. doi: 10.1186/1476-4598-13-102.

 

・Takahashi M, Hayashida T, Okazaki H, Miyao K, Jinno H, Kitagawa Y. Loss of B-cell Translocation Gene 2 expression in Estrogen Receptor Positive Breast Cancer Predicts Tamoxifen Resistance. Cancer Sci. 2014 Jun;105(6):675-82. doi: 10.1111/cas.12410.

 

・Seo Y, Ishii Y, Ochiai H, Fukuda K, Akimoto S, Hayashida T, Okabayashi K, Tsuruta M, Hasegawa H, Kitagawa Y. Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS/BRAF mutational status in colorectal cancer. Oncol Rep. 2014 May;31(5):2115-22. doi: 10.3892/or.2014.3077.

 

・Nishiyama R, Shinoda M, Tanabe M, Oshima G, Takano K, Miyasho T, Fuchimoto Y, Yamada S, Inoue T, Shimada K, Suda K, Tanaka M, Hayashida T, Yagi H, Kitago M, Obara H, Itano O, Takeuchi H, Kawachi S, Maruyama I, Kitagawa Y. Hemoadsorption of high-mobility group box chromosomal protein 1 using a column for large animals. Eur Surg Res. 2013;51(3-4):181-90. doi: 10.1159/000357563.

 

・Kohei Shigeta, Tetsu Hayashida, Yoshinori Hoshino, Koji Okabayashi, Takashi Endo, Yoshiyuki Ishii, Hirotoshi Hasegawa, Yuko Kitagawa, Expression of epidermal growth factor receptor detected by cetuximab indicates its efficacy to inhibit in vitro and in vivo proliferation of colorectal cancer cells, PLoS ONE 2013, 8(6): e66302

 

・Jinno H, Matsuda S, Hayashida T, Takahashi M, Hirose S, Ikeda T, Kitagawa Y. Differential Pathological Response to Preoperative Chemotherapy across Breast Cancer Intrinsic Subtypes. Chemotherapy. 2012 Nov 27;58(5):364-370.

 

・Takahashi M, Jinno H, Hayashida T, Sakata M, Asakura K, Kitagawa Y., Correlation Between Clinical Nodal Status and Sentinel Lymph Node Biopsy False Negative Rate After Neoadjuvant Chemotherapy., World J Surg. 2012 Dec;36(12):2847-52.

 

・Oshima G, Shinoda M, Tanabe M, Ebinuma H, Nishiyama R, Takano K, Yamada S, Miyasho T, Masugi Y, Matsuda S, Suda K, Fukunaga K, Matsubara K, Hibi T, Yagi H, Hayashida T, Yamagishi Y, Obara H, Itano O, Takeuchi H, Kawachi S, Saito H, Hibi T, Maruyama I, Kitagawa Y., Increased plasma levels of high mobility group box 1 in patients with acute liver failure, Eur Surg Res. 2012;48(3):154-62.

 

・ Hirohito Seki, Tetsu Hayashida, Hiromitsu Jinno, Shigemichi Hirose, Michio Sakata, Maiko Takahashi, Shyamala Maheswaran, Makio Mukai, Yuko Kitagawa, HOXB9 expression promoting tumor cell proliferation and angiogenesis is associated with clinical outcomes in breast cancer patients, Ann Surg Oncol. 2012 Jun;19(6):1831-40.

 

・Yoshihiro Ono, Tetsu Hayashida, Ayano Konagai, Hiroshi Okazaki, Shigeyuki Kawachi, Minoru Tanabe, Masahiro Shinoda, Hiromitsu Jinno Hirotoshi Hasegawa, Masaki Kitajima, and Yuko Kitagawa, Direct inhibition of the transforming growth factor ß pathway by protein-bound polysaccharide through inactivation of smad2 signaling, Cancer Sci. 2012 Feb; 103(2):317-324

 

・Naokazu Chiba , Valentine Comaills , Bunsyo Shiotani , Fumiyuki Takahashi , Toshiyuki Shimada , Ken Tajima , Daniel Winokur , Tetsu Hayashida , Henning Willers , Elena Brachtel , Maria Vivanco , Daniel Haber , Lee Zou , Shyamala Maheswaran, HOXB9 induces EMT-associated radioresistance by promoting activation of the ATM pathway, Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2760-5.

 

・Ono Y, Kawachi S, Hayashida T, Wakui M, Tanabe M, Itano O, Obara H, Shinoda M, Hibi T, Oshima G, Tani N, Mihara K, Kitagawa Y.  The influence of donor age on liver regeneration and hepatic progenitor cell populations. Surgery. 2011 Aug; 150(2):154-61.

 

・Fumiyuki Takahashi, Naokazu Chiba, Tetsu Hayashida, Hiroyuki Moriyama, Motomi Takahashi, Ken Tajima, Elena J. Edelman, Sridhar Ramaswamy, Elena Brachtel, Shyamala Maheswaran, Breast tumor progression induced by loss of BTG2 expression is inhibited by targeted therapy with the ErbB/HER inhibitor lapatinib, Oncogene. 2011 Jul 7;30(27):3084-95.

 

・Jinno H, Sakata M, Hayashida T, Takahashi M, Sato T, Seki H, Kitagawa Y. Primary systemic chemotherapy of breast cancer: indication and predictive factors. Breast Cancer. 2011 Apr;18(2):74-9.

 

・Yang CP, Hayashida T, Forster N, Li C, Shen D, Maheswaran S, Chen L, Anderson KS, Ellisen L, Sgroi DC, Schmidt EV.The integrin {alpha}v{beta}3-5 ligand MFG-E8 is a p63/p73 target gene in triple negative breast cancers but exhibits suppressive functions in ER+ and erbB2+ breast cancers. Cancer Res. 2011 Feb 1;71(3):937-45.

 

∙Hayashida T, Takahashi F, Chiba N, Brachtel E, Takahashi M, Godin-Heymann N, Gross KW, Vivanco MM, Wijendran V, Shioda T, Sgroi D, Donahoe PK, Maheswaran S. HOXB9, a gene overexpressed in breast cancer, promotes tumorigenicity and lung metastasis. Proc Natl Acad Sci U S A. 2010 Jan 19;107(3):1100-5

 

∙Hayashida T, Jinno H, Kitagawa Y, Kitajima M., Cooperation of cancer stem cell properties and epithelial-mesenchymal transition in the establishment of breast cancer metastasis. J Oncol. 2011;2011:591427.

 

・Onishi T, Jinno H, Takahashi M, Hayashida T, Sakata M, Nakahara T, Shigematsu N, Mukai M, Kitagawa Y. Non-Sentinel Lymph Node Status and Prognosis of Breast Cancer Patients with Micrometastatic Sentinel Lymph Nodes. Eur Surg Res. 2010;45(3-4):344-9.

 

・ Jinno H, Sakata M, Hayashida T, Takahashi M, Sato T, Seki H, Kitagawa Y. Primary systemic chemotherapy of breast cancer: indication and predictive factors.  Breast Cancer. 2011 Apr;18(2):74-9.

 

∙Takano K, Shinoda M, Tanabe M, Miyasho T, Yamada S, Ono S, Masugi Y, Suda K, Fukunaga K, Hayashida T, Hibi T, Obara H, Takeuchi H, Kawachi S, Kawasako K, Okamoto M, Yokota H, Maruyama I, Kitagawa Y.  Protective Effect of High-Mobility Group Box 1 Blockade on Acute Liver Failure in Rats: (Hmgb1 Blockade for Rat Acute Liver Failure). Shock. 2010 Dec;34(6):573-9..

 

∙Uchida H, Yamazaki K, Fukuma M, Yamada T, Hayashida T, Hasegawa H, Kitajima M, Kitagawa Y, Sakamoto M. Overexpression of leucine-rich repeat-containing G protein-coupled receptor 5 in colorectal cancer. Cancer Sci. 2010 Jul;101(7):1731-7

 

∙Hayashida T, Jinno H, Sakata M, Takahashi M, Onishi T, Seki H, Sato T, Nakahara T, Shigematsu N, Mukai M, Hibi T, Kitajima M, Kitagawa Y. Superiority of Radioisotope over Blue Dye for Sentinel Lymph Node Detection in Breast Cancer. Eur Surg Res. 2010 Jan 29;44(2):111-116.

 

∙Jinno H, Sakata M, Hayashida T, Takahashi M, Mukai M, Ikeda T, Kitagawa Y. A phase II trial of capecitabine and docetaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as preoperative treatment in women with stage II/III breast cancer. Ann Oncol (2010) 21 (6): 1262-1266.

 

∙Abe Y, Urakami H, Ostanin D, Zibari G, Hayashida T, Kitagawa Y,  Grisham MB, Induction of Foxp3-Expressing Regulatory T-Cells by Donor Blood Transfusion Is Required for Tolerance to Rat Liver Allografts. PLoS ONE 2009, 4(11): e7840.

 

∙Gupta V, Yeo G, Kawakubo H, Rangnekar V, Ramaswamy P, Hayashida T, MacLaughlin DT, Donahoe PK, and Maheswaran S., Mullerian-inhibiting substance induces Gro-beta expression in breast cancer cells through a nuclear factor-kappaB-dependent and Smad1-dependent mechanism., Cancer Res. 2007 Mar 15;67(6):2747-56.

 

∙Kawakubo H, Brachtel E, Hayashida T, Yeo G, Kish J, Muzikansky A, Walden PD, and Maheswaran S., Loss of B-cell translocation gene-2 in estrogen receptor-positive breast carcinoma is associated with tumor grade and overexpression of cyclin d1 protein., Cancer Res. 2006 Jul 15;66(14):7075-82.

 

∙Hayashida T, Ueda M, Aiura K, Tada H, Onizuka M,  Seno M, Yamada H, and Kitajima M, Anti-angiogenic effect of an insertional fusion protein of human basic fibroblast growth factor and ribonuclease-1 by three-dimensional tube formation assay and mouse dorsal air sac assay. Protein Eng Des Sel. 2005 Jul;18(7):321-7.

 

 

 

bottom of page